Enlivex (ENLV) Cash from Restructuring (2015 - 2016)
Enlivex (ENLV) posted quarterly Cash from Restructuring of -$125000.0 for Q2 2016, down 757.89% year-over-year from $19000.0 in Q3 2015, and down 757.89% quarter-over-quarter from $19000.0 in Q4 2015.
Enlivex (ENLV) Cash from Restructuring (2015 - 2016) Analysis & Trends
Enlivex's Cash from Restructuring history runs 2 years deep, the most recent figure standing at -$125000.0 for Q2 2016.
- In Q2 2016, Cash from Restructuring fell 757.89% year-over-year to -$125000.0; the TTM figure through Dec 2016 stood at -$106000.0 (changed N/A YoY), while the FY2016 annual figure was -$70000.0, down 200.0% from the prior year.
- Cash from Restructuring for Q2 2016 stood at -$125000.0, down from $19000.0 in the prior quarter.
- The five-year high for Cash from Restructuring was $19000.0 in Q2 2015, with the low at -$125000.0 in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Enlivex | 4.49 Mn | -1.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | -125,000.00 |
| Dec 31, 2015 | 19,000.00 |
| Sep 30, 2015 | 19,000.00 |
| Jun 30, 2015 | 19,000.00 |